

Vanda Pharmaceuticals Inc.

Form SC 13G/A

February 14, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Schedule 13G/A**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

Vanda Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

921659108

(CUSIP Number)

December 31, 2017

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but

shall be subject to all other provisions of the Act (however, see the Notes).

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

CUSIP No. **921659108** 13G/A Page 2 of 8 Pages

**NAMES OF**  
**1.REPORTING**  
**PERSONS**  
 Great Point Partners,  
 LLC  
 I.R.S.  
**IDENTIFICATION**  
**NO. OF ABOVE**  
**PERSON**  
 (ENTITIES ONLY):  
 37-1475292  
**CHECK THE**  
**APPROPRIATE**

**2.BOX IF A**  
**MEMBER OF A**  
**GROUP**  
 (a) ☐  
 (b) ☐

**3.SEC USE ONLY**

**CITIZENSHIP OR**  
**4.PLACE OF**  
**ORGANIZATION**  
 USA

<b>NUMBER OF SHARES</b>	<b>5.SOLE VOTING POWER</b>
	0
<b>BENEFICIALLY</b>	<b>6.SHARED VOTING POWER</b>
	797,531
<b>OWNED BY EACH</b>	<b>7.SOLE DISPOSITIVE POWER</b>
	0
<b>REPORTING PERSON</b>	<b>8.SHARED DISPOSITIVE POWER</b>
<b>WITH</b>	797,531

**AGGREGATE**  
**AMOUNT**  
**BENEFICIALLY**  
**9. OWNED BY**  
**EACH**  
**REPORTING**  
**PERSON**  
 797,531  
**10.** ☐

**CHECK  
BOX IF  
THE  
AGGREGATE  
AMOUNT  
IN ROW (9)  
EXCLUDES  
CERTAIN  
SHARES**

(See  
Instructions)

**PERCENT OF  
CLASS**

**11. REPRESENTED  
BY AMOUNT IN  
ROW (9)**

1.78%<sup>1</sup>

**12. TYPE OF  
REPORTING  
PERSON (See**

Instructions)

IA

<sup>1</sup>Based on a total of 44,927,525 shares outstanding, as reported by the Issuer in its Form 10-Q filed with the SEC on November 8, 2017.

CUSIP No. **921659108** 13G/A Page 3 of 8 Pages

**NAMES OF  
1.REPORTING  
PERSONS**  
Dr. Jeffrey R. Jay,  
M.D.  
I.R.S.  
**IDENTIFICATION  
NO. OF ABOVE  
PERSON  
(ENTITIES ONLY):**

**CHECK THE  
APPROPRIATE**  
**2.BOX IF A  
MEMBER OF A  
GROUP**  
(a) ☐  
  
(b) ☐

**3.SEC USE ONLY**

**CITIZENSHIP OR  
4.PLACE OF  
ORGANIZATION**  
USA

<b>NUMBER OF SHARES</b>	<b>5.SOLE VOTING POWER</b>
	0
<b>BENEFICIALLY</b>	<b>6.SHARED VOTING POWER</b>
	797,531
<b>OWNED BY EACH</b>	<b>7.SOLE DISPOSITIVE POWER</b>
	0
<b>REPORTING PERSON</b>	<b>8.SHARED DISPOSITIVE POWER</b>
<b>WITH</b>	797,531

**AGGREGATE  
AMOUNT  
BENEFICIALLY**  
**9. OWNED BY  
EACH  
REPORTING  
PERSON**  
797,531

- CHECK  
BOX IF  
THE  
AGGREGATE  
AMOUNT  
IN ROW  
10. (9)  
EXCLUDES  
CERTAIN  
SHARES  
(See  
Instructions)**
- PERCENT OF  
CLASS  
11. REPRESENTED  
BY AMOUNT IN  
ROW (9)  
1.78%<sup>1</sup>**
- TYPE OF  
REPORTING  
12. PERSON (See  
Instructions)  
IN**

CUSIP No. **921659108 13G/A** Page 4 of 8 Pages

**NAMES OF  
1. REPORTING  
PERSONS**  
Mr. David Kroin  
I.R.S.  
**IDENTIFICATION  
NO. OF ABOVE  
PERSON  
(ENTITIES ONLY):**

**CHECK THE  
APPROPRIATE**  
**2. BOX IF A  
MEMBER OF A  
GROUP**  
(a) ☐  
  
(b) ☐

**3. SEC USE ONLY**

**CITIZENSHIP OR**  
**4. PLACE OF  
ORGANIZATION**  
USA

<b>NUMBER OF SHARES</b>	<b>5. SOLE VOTING POWER</b>
	0
<b>BENEFICIALLY</b>	<b>6. SHARED VOTING POWER</b>
	797,531
<b>OWNED BY EACH</b>	<b>7. SOLE DISPOSITIVE POWER</b>
	0
<b>REPORTING PERSON</b>	<b>8. SHARED DISPOSITIVE POWER</b>
<b>WITH</b>	797,531

**AGGREGATE  
AMOUNT  
BENEFICIALLY**  
**9. OWNED BY  
EACH  
REPORTING  
PERSON**  
797,531  
**10. CHECK ☐  
BOX IF**

**THE  
AGGREGATE  
AMOUNT  
IN ROW (9)  
EXCLUDES  
CERTAIN  
SHARES**

(See  
Instructions)

**PERCENT OF  
CLASS**

**11. REPRESENTED  
BY AMOUNT IN  
ROW (9)**

1.78%<sup>1</sup>

**12. TYPE OF  
REPORTING  
PERSON (See**

Instructions)

IN



CUSIP No. **921659108 13G/A** Page 5 of 8 Pages

**Item 1.**

(a) Name of Issuer

Vanda Pharmaceuticals Inc.

(b) Address of Issuer's Principal Executive Offices

2200 Pennsylvania Ave NW, Suite 300E, Washington DC 20037

**Item 2.**

(a) Name of Person Filing

Great Point Partners, LLC  
Dr. Jeffrey R. Jay, M.D.  
Mr. David Kroin

The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2018, a copy of which is filed with this Schedule 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

(b) Address of Principal Business Office, or if none, Residence

The address of the principal business office of each of the Reporting Persons is

165 Mason Street, 3rd Floor  
Greenwich, CT 06830

(c) Citizenship

Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States.

(d) Title of Class of Securities

Common Stock

(e) CUSIP Number

921659108

**Item 3. If this  
statement is**

**filed pursuant  
to  
§240.13d-1(b)  
or 240.13d.2(b)  
or (c), check  
whether the  
person filing is  
a:**

Not Applicable.

- (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
- (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c).
- (d) ☐ Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

CUSIP No. **921659108 13G/A** Page 6 of 8 Pages

- (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
- (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
- (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

**Item 4. Ownership**

Not Applicable.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person:**

Not Applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable.

**Item 9. Notice of Dissolution of Group**

Not Applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

CUSIP No. **921659108 13G/A** Page 7 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2018

GREAT POINT PARTNERS,  
LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.  
Dr. Jeffrey R. Jay, M.D.,  
as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.  
DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin  
MR. DAVID KROIN

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree as follows:

- (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and
- (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Date: February 14, 2018

GREAT POINT PARTNERS,  
LLC

By: /s/ Dr. Jeffrey R. Jay, M.D.  
Dr. Jeffrey R. Jay, M.D.,  
as senior managing member

/s/ Dr. Jeffrey R. Jay, M.D.  
DR. JEFFREY R. JAY, M.D.

/s/ Mr. David Kroin  
MR. DAVID KROIN